Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP

The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this comb...

Descripción completa

Detalles Bibliográficos
Autores principales: McFall, Thomas, Trogdon, Michael, Guizar, Anita C., Langenheim, John F., Sisk-Hackworth, Laura, Stites, Edward C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684405/
https://www.ncbi.nlm.nih.gov/pubmed/36418474
http://dx.doi.org/10.1038/s41698-022-00329-w
_version_ 1784835273080700928
author McFall, Thomas
Trogdon, Michael
Guizar, Anita C.
Langenheim, John F.
Sisk-Hackworth, Laura
Stites, Edward C.
author_facet McFall, Thomas
Trogdon, Michael
Guizar, Anita C.
Langenheim, John F.
Sisk-Hackworth, Laura
Stites, Edward C.
author_sort McFall, Thomas
collection PubMed
description The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective.
format Online
Article
Text
id pubmed-9684405
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96844052022-11-25 Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP McFall, Thomas Trogdon, Michael Guizar, Anita C. Langenheim, John F. Sisk-Hackworth, Laura Stites, Edward C. NPJ Precis Oncol Brief Communication The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective. Nature Publishing Group UK 2022-11-23 /pmc/articles/PMC9684405/ /pubmed/36418474 http://dx.doi.org/10.1038/s41698-022-00329-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
McFall, Thomas
Trogdon, Michael
Guizar, Anita C.
Langenheim, John F.
Sisk-Hackworth, Laura
Stites, Edward C.
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
title Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
title_full Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
title_fullStr Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
title_full_unstemmed Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
title_short Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
title_sort co-targeting kras g12c and egfr reduces both mutant and wild-type ras-gtp
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684405/
https://www.ncbi.nlm.nih.gov/pubmed/36418474
http://dx.doi.org/10.1038/s41698-022-00329-w
work_keys_str_mv AT mcfallthomas cotargetingkrasg12candegfrreducesbothmutantandwildtyperasgtp
AT trogdonmichael cotargetingkrasg12candegfrreducesbothmutantandwildtyperasgtp
AT guizaranitac cotargetingkrasg12candegfrreducesbothmutantandwildtyperasgtp
AT langenheimjohnf cotargetingkrasg12candegfrreducesbothmutantandwildtyperasgtp
AT siskhackworthlaura cotargetingkrasg12candegfrreducesbothmutantandwildtyperasgtp
AT stitesedwardc cotargetingkrasg12candegfrreducesbothmutantandwildtyperasgtp

Ejemplares similares